New molecular entity: Tocilizumab (Actemra) was approved in January 2010, for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor antagonist therapies.
This January, FDA approved tocilizumab intravenous infusion for marketing in the United States. Tocilizumab is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies (ie, infliximab). Rheumatoid arthritis, a chronic disease mainly characterized by inflammation of the lining or synovium of the joints, is estimated to affect 1.3 million Americans.
Efficacy. The efficacy of tocilizumab has been assessed in 5 multicenter, randomized, double-blind, placebo- or active-controlled trials. Each trial enrolled adult patients with rheumatoid arthritis having at least 8 tender and 6 swollen joints at baseline. Administered every 4 weeks, tocilizumab has been studied as monotherapy, in combination with methotrexate in patients not responding adequately to disease modifying anti-rheumatic drugs (DMARD), or in combination with methotrexate in patients not responding to one or more TNF antagonist therapies. In each of these trials, the proportion of patients achieving the American College of Rheumatology (ACR) 20, 50, and 70 end points at 24 weeks while taking tocilizumab 8 mg/kg was greater than control patients receiving either placebo or methotrexate. Typically, patients receiving tocilizumab 4 mg/kg had a poorer response in clinical trials than those receiving 8 mg/kg.
Safety. Common side effects of tocilizumab (occurring in greater than 5% of treated patients) include upper respiratory tract infections (common cold, sinus infections), headache, and hypertension. Other serious side effects of tocilizumab include perforation of the gastrointestinal tract, changes in blood test results (elevated liver function tests [AST or ALT], elevated serum lipids [total or low-density lipoprotein cholesterol or triglycerides], reduced neutrophil and platelet counts), increased risk of hepatitis B infection in those already carrying the virus, increased risk of nervous system problems (development of multiple sclerosis), malignancies, and serious allergic reactions. Patients treated with tocilizumab are also at an increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis, bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, tocilizumab therapy should be stopped until the infection is controlled.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
Iowa Expands PBM Legislation to Address Concerns of Independent Pharmacies
May 16th 2025A new law in Iowa, if signed by the governor, will mandate 100% pass-through of rebates, increased financial transparency, and a minimal payment for pharmacies. Critics say it will be the most costly mandate in the state’s history.
Read More
Is Arkansas’ New PBM Law the Right Path Forward for Reform? No One Knows Yet
May 9th 2025It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are unsure about the impact of Arkansas’ law banning PBMs from owning pharmacies.
Read More